First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).

Shaan Dudani,Jeffrey Graham,Connor Wells,Ziad Bakouny,Sumanta K. Pal,Nazli Dizman,Frede Donskov,Camillo Porta,Guillermo Velasco,Aaron Richard Hansen,Marco Adelmo James Iafolla,Benoit Beuselinck,Ulka N. Vaishampayan,Lori Wood,Elizabeth Chien Hern Liow,Flora Yan,Takeshi Yuasa,Georg A. Bjarnason,Toni K. Choueiri,Daniel Yick Chin Heng

First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).

2019

4577Background: In mRCC, ipilimumab and nivolumab (ipi-nivo) is a 1L treatment option. Recent data have also shown efficacy of 1L IO-VEGF (IOVE) inhibitor combinations. Comparative data between the...

Keywords:

Renal cell carcinoma
Medicine
Oncology
Internal medicine
Ipilimumab
treatment options
first line
Nivolumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations